Study S002552

Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00530309
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Status: COMPLETED
Enrollment: 40
Start: 2007-08-01
Primary completion: 2008-04-17
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:GSK716155 for injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Plasma concentrations and PD parameters over time and at the end of study [Up to Week 9]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018591	Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Young MA, Postgraduate medicine	2014	Other trial	PMID 25387217 DOI	cites ClinicalTrials.gov:NCT00530309; registry reference DERIVED:25387217
R0024741	Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Seino Y, Current medical research and opinion	2009	Randomized trial	PMID 19863477 DOI	cites ClinicalTrials.gov:NCT00530309; registry reference BACKGROUND:19863477